| Zuhua Chen,Lin Shen. Advantages and limitations in the establishment and utilization of patient-derived xenografts in gastric cancer. Oncol Transl Med, 2017, 3: 3-9. |
| 人源化胃癌移植瘤模型在建立和应用中的优势和局限 |
| Advantages and limitations in the establishment and utilization of patient-derived xenografts in gastric cancer |
| Received:August 26, 2016 Revised:January 22, 2017 |
| DOI：10.1007/s10330-016-0187-7 |
| 中文关键词: 人源化移植瘤模型；胃癌；临床前研究 |
| 英文关键词: patient-derived tumor xenograft (PDTX); gastric cancer (GC); preclinical research |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Zuhua Chen | Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China | 1411110423@bjmu.edu.cn | | Lin Shen* | Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China | lin100@medmail.com.cn |
|
| Hits: 10817 |
| Download times: 12515 |
| 中文摘要: |
| 晚期胃癌异质性高、治疗策略少且频发耐药，其预后不尽人意。由于传统肿瘤细胞系与患者原发肿瘤在基因组变异和表达谱中的一致性欠佳，肿瘤细胞系在转化研究中的应用有限。人源化肿瘤移植瘤模型可成功保留患者原发肿瘤的组织病理学，分子遗传学特征和治疗敏感性，成为近十年来转化研究关注的热点。尽管如此，由于建模时间长、易发生淋巴瘤转化、缺乏免疫微环境以及不同物种药代动力学的差异，很大程度上限制了人源化移植瘤模型的广泛建立和应用。在本篇综述中，我们总结了人源化胃癌移植瘤模型的建立和鉴定情况，并阐述其在新药疗效的评价、生物标志物的探索、靶向治疗耐药机制的阐明以及临床治疗指导中的优势与局限。 |
| 英文摘要: |
| Owing to the high genetic heterogeneity of tumors, small number of therapeutic strategies available, and
frequent presentation of drug resistance, the prognosis for patients with advanced gastric cancer (AGC)
are unsatisfactory. The utility of traditional cancer cell lines in translational research is limited by their poor
correspondence to the genomic alterations and expression profiles that occur in actual patient tumors. In
the last decade, increasing attention has been given to patient-derived tumor xenografts (PDTXs), which
can faithfully recapitulate the histopathology, molecular characteristics, and therapeutic responses of the
patient’s tumor. However, the widespread development and utilization of PDTXs is restricted by factors
such as the timeframe of establishment, lymphoma transformation during passaging, the immunodeficient
microenvironment, and pharmacokinetic differences between mice and humans. In this review, we
summarize the establishment and characterization of PDTX models for gastric cancer (GC). We then
weigh the advantages and limitations of PDTXs when used to evaluate novel compounds, identify effective
biomarkers, demonstrate resistance mechanisms, and predict clinical outcomes. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|